| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
BRD4354 targets HDAC5 and HDAC9. It is a zinc-chelating, reversible inhibitor that binds to the active sites of these class IIa HDACs. By inhibiting HDAC5 and HDAC9, the compound modulates the acetylation of histones and other proteins, leading to changes in gene expression. Its selectivity for HDAC5/9 over other HDAC isoforms makes it a valuable tool for studying the specific roles of these enzymes.
|
|---|---|
| ln Vitro |
BRD 4354 has an IC50 of 0.85 μM for HDAC5 and 1.88 μM for HDAC9, making it a fairly effective inhibitor of both enzymes. In addition, at higher concentrations (3.88-13.8 μM), BRD 4354 inhibits HDACs 4, 6, 7, and 8, but less so (IC50>40 μM) than it does the other class I HDACs 1, 2, and 3 [1].
In vitro, BRD4354 has been shown to be a potent inhibitor of HDAC5 and HDAC9. It inhibits HDAC5 with an IC50 of 0.85 µM and HDAC9 with an IC50 of 1.88 µM. At higher concentrations, it also inhibits other class IIa HDACs. |
| ln Vivo |
In vivo, BRD4354 is being evaluated for its potential therapeutic applications. As an HDAC5/9 inhibitor, it may have effects on various biological processes, including inflammation, metabolism, and cancer.
|
| Enzyme Assay |
In vitro enzyme or receptor binding (non-cell) assays for BRD4354 involve measuring its direct inhibition of HDAC5 and HDAC9 enzymatic activity. The assay uses a purified recombinant HDAC enzyme and a fluorogenic peptide substrate. The deacetylation of the substrate releases a fluorescent product. The compound is incubated with the enzyme and substrate, and the decrease in fluorescence is measured to determine the IC50. Selectivity is assessed by testing the compound against a panel of other HDAC isoforms.
|
| Cell Assay |
In vitro cell-based assays for BRD4354 are performed using various cell lines. Cells are treated with the compound, and the acetylation of HDAC5/9 substrates is assessed by Western blotting. Cell viability and proliferation are measured using standard assays.
|
| Animal Protocol |
In vivo animal experiments for BRD4354 are conducted using mouse models of disease. The compound is administered, and its effects on disease parameters are assessed. The specific experimental design depends on the research question being addressed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of BRD4354 have been characterized to support its use as a research tool. The compound has a molecular weight of 382.89 and a formula of C₂₁H₂₃ClN₄O. It is soluble in DMSO. Specific PK parameters, such as half-life and bioavailability, are determined in preclinical studies via LC-MS/MS analysis of plasma samples.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for BRD4354 are typical of a research compound. It is generally well-tolerated at effective doses. The safety profile is being evaluated in the context of its use as a research tool to study HDAC5/9 biology.
|
| References | |
| Additional Infomation |
5-Chloro-7-[(4-ethyl-1-piperazinyl)-(3-pyridyl)methyl]-8-quinolinol is an organochlorine compound belonging to the quinoline class of compounds.
Other information: BRD4354 is a research compound used to study the role of HDAC5 and HDAC9 in various diseases. It is available from chemical suppliers for preclinical research purposes. |
| Molecular Formula |
C21H23CLN4O
|
|---|---|
| Molecular Weight |
382.886523485184
|
| Exact Mass |
382.156
|
| CAS # |
315698-07-8
|
| Related CAS # |
BRD 4354 ditrifluoroacetate
|
| PubChem CID |
3516032
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
473
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1=CN=CC=C1)(N1CCN(CC)CC1)C1C=C(Cl)C2C=CC=NC=2C=1O
|
| InChi Key |
XAFSFXYJOJWLJD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H23ClN4O/c1-2-25-9-11-26(12-10-25)20(15-5-3-7-23-14-15)17-13-18(22)16-6-4-8-24-19(16)21(17)27/h3-8,13-14,20,27H,2,9-12H2,1H3
|
| Chemical Name |
5-chloro-7-[(4-ethylpiperazin-1-yl)-pyridin-3-ylmethyl]quinolin-8-ol
|
| Synonyms |
BRD-4354; BRD 4354; BRD4354
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~32.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6117 mL | 13.0586 mL | 26.1172 mL | |
| 5 mM | 0.5223 mL | 2.6117 mL | 5.2234 mL | |
| 10 mM | 0.2612 mL | 1.3059 mL | 2.6117 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
